Abstract

Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is increasing. Vancomycin and teicoplanin are 2 intravenous glycopeptides appropriate for its treatment.

There is no human study comparing teicoplanin and vancomycin for the treatment of MRSA endocarditis. Between 1996 and 2006, 51 MRSA endocarditis patients were treated at the authors' hospital.

There were 29 patients with nosocomial infection; 15 were treated with teicoplanin.

Teicoplanin was used as the first therapeutic agent in 3 patients because of renal insufficiency. Vancomycin was used as ...

Esta siendo redirigido al contenido completo...